UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 30, 2023, Syndax Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that Neil Gallagher, M.D., Ph.D., will join the Company as President, Head of Research and Development, effective April 10, 2023. On March 29, 2023, Briggs W. Morrison M.D., President, Head of Research and Development of the Company, notified the Company of his intention to resign from his position as President, Head of Research and Development. Dr. Morrison will continue with the Company through April 15, 2023, before transitioning to serve in a consulting capacity for three months. Dr. Morrison remains a Class III director of the Company and is currently serving a three-year term until the Company’s 2025 Annual Meeting, or until his respective successor is duly elected and qualified or until his earlier death, resignation or removal.
Prior to joining the Company, Dr. Gallagher served as Chief Medical Officer, VP Head of Development at AbbVie, Inc. and previously served as AbbVie’s Head of Global Oncology Development. Prior to joining AbbVie, he served as Head of Development, Oncology and Inflammation at Amgen, Inc. Dr. Gallagher received a B.A. as well as his MB, BCh and BAO from Trinity College, Dublin, and his PhD from the Institute for Cancer Studies, University of Birmingham, Birmingham, UK.
There are no arrangements or understandings with the Company pursuant to which Dr. Gallagher was appointed to serve as President, Head of Research and Development. There are no family relationships between Dr. Gallagher and any director or executive officer of the Company, and there are no related party transactions of the kind described in Item 404(a) of Regulation S-K in which Dr. Gallagher was a participant.
In connection with his appointment, the Company entered into an employment agreement with Dr. Gallagher, effective March 30, 2023 (the “Employment Agreement”), providing for the terms of his employment, including (i) an annual base salary of $530,000; (ii) an annual target bonus equal to 45% of his base salary, which bonus will be pro-rated for 2023; and (iii) an inducement stock option award to purchase 250,000 shares of the Company’s common stock, exercisable at a price per share equal to the closing price of the Company’s common stock on the Nasdaq Global Select Market on April 10, 2023, the date of grant. Twenty-five percent (25%) of the shares subject to such option shall vest on the one-year anniversary of the vesting commencement date, and one forty-eighth (1/48th) of the shares of common stock subject to such option shall vest monthly thereafter on the last day of each month over the following thirty-six (36) months until all of the shares subject to such option are fully vested, subject to continued service.
Dr. Gallagher’s employment agreement further provides that in the event his employment is terminated without “cause,” as defined in his employment agreement, or he terminates his employment for “good reason,” as defined in his employment agreement, he is entitled to (i) a lump sum severance payment equal to nine months base salary, (ii) payment on his behalf of up to nine months of health insurance benefits continuation and (iii) with respect to equity awards granted to Dr. Gallagher prior to the date of his termination, accelerated vesting and the lapse of any reacquisition or repurchase rights that the Company holds with respect to such equity awards for the portion of such equity awards that would have otherwise vested within the 12-month period following the date of Dr. Gallagher’s termination were he to remain employed with the Company during such 12-month period. If Dr. Gallagher’s employment is terminated without cause or he terminates his employment for good reason within three months prior to, or 12 months after, a “change in control” of the Company, as defined in his employment agreement, he is instead entitled to (a) a lump sum severance payment equal to the sum of 12 months base salary and 100% of the greater of (1) the average annual target performance bonus paid to him for the preceding three years or (2) his annual target performance bonus in effect as of the change in control, (b) payment on his behalf of up to 12 months of health insurance benefits continuation and (c) full accelerated vesting on all of his unvested options and the lapse of any reacquisition or repurchase rights that the Company holds with respect to any other equity award granted to him pursuant to any of the Company’s equity incentive plans. To receive his severance benefits, Dr. Gallagher must sign a general release of claims.
Dr. Gallagher’s employment agreement further provides that in the event the severance and other benefits provided for or otherwise payable to him constitute “parachute payments” within the meaning of Section 280G of the Code and are subject to the excise tax imposed by Section 4999 of the Code, the Company will pay either (i) Dr. Gallagher’s severance benefits under the employment agreement in full or (ii) only a part of Dr. Gallagher’s severance benefits under the employment agreement such that Dr. Gallagher receives the largest payment possible without the imposition of the excise tax, in each case, depending upon which alternative would result in Dr. Gallagher receiving the greater net after-tax payment.
In connection with his appointment as President, Head of Research and Development, Dr. Gallagher entered into the Company’s standard form of Indemnification Agreement, a copy of which was filed as Exhibit 10.21 to the Registration Statement on Form S-1 (File No. 333-208861) filed with the SEC on January 4, 2016.
The foregoing description of the Employment Agreement is qualified in its entirety by reference to the complete text of such agreement, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein. A copy of the Company’s
press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 7.01 Regulation FD Disclosure.
A copy of the Company’s press release announcing the foregoing is attached to this Current Report on Form 8-K as Exhibit 99.1. The information in this Item 7.01 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference to such filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit
|
Description
|
10.1 |
|
99.1 |
|
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Syndax Pharmaceuticals, Inc. |
|
|
|
|
Date: |
March 30, 2023 |
By: |
/s/ Michael A. Metzger |
|
|
|
Michael A. Metzger |
Exhibit 10.1
EXECUTIVE EMPLOYMENT AGREEMENT
This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of the 30th day of March, 2023 (the “Execution Date”), between NEIL GALLAGHER, M.D., Ph.D. (“Executive”) and Syndax Pharmaceuticals, Inc. (the “Company”). Certain capitalized terms used in this Agreement are defined in Article 7.
RECITALS
AGREEMENT
NOW, THEREFORE, in consideration of the mutual promises contained herein, the Company and Executive agree as follows:
2
3.1 Severance Benefits. Upon a Change in Control Termination, and subject to the limitations and conditions set forth in this Agreement, Executive shall be eligible to receive the benefits set forth in this Article 3. The receipt of any severance payments or benefits pursuant to this Agreement is subject to Executive signing and not revoking a separation agreement and general release of claims (the “Release”), in substantially the form attached hereto and incorporated herein as Exhibit A, Exhibit B or Exhibit C, as appropriate, which Release must become effective and irrevocable no later than the sixtieth (60th) day following Executive’s termination of employment (the “Release Deadline Date”). If the Release does not become effective and irrevocable by the Release Deadline Date, Executive will forfeit any right to any severance payments or benefits under this Agreement. In no event will severance payments or benefits be paid or provided until the Release actually becomes effective and irrevocable
3
4
5
6
7
8
OTHER RIGHTS AND BENEFITS
9
Unless otherwise provided, for purposes of this Agreement, the following definitions shall apply:
10
The term Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company. Notwithstanding the foregoing or any other provision of this Agreement, the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any affiliate and the participant shall supersede the foregoing definition with respect to stock awards subject to such agreement (it being understood, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply).
11
12
13
14
15
IN WITNESS WHEREOF, the parties have executed this Agreement on the Effective Date written above.
|
|
|
|
|
|
|
|
|
Syndax Pharmaceuticals, Inc. |
|
|
|
|
|
EXECUTIVE |
||
|
|
|
|
|
||||
By: |
|
/s/ Luke J. Albrecht |
|
|
|
|
By: |
/s/ Neil Gallagher, M.D., Ph.D. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name: |
|
Luke J. Albrecht |
|
|
|
|
Name: |
Neil Gallagher, M.D., Ph.D. |
Title: |
|
General Counsel |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exhibit A: Release (Individual Termination – Age 40 or Older)
Exhibit B: Release (Individual and Group Termination – Under Age 40)
Exhibit C: Release (Group Termination – Age 40 or Older)
EXHIBIT A
RELEASE
(INDIVIDUAL TERMINATION – AGE 40 OR OLDER)
Certain capitalized terms used in this Release are defined in the Executive Employment Agreement (the “Agreement”) which I have executed and of which this Release is a part.
I hereby confirm my obligations under the Confidentiality Agreement (or other comparable agreement that I have signed, if any).
Except as otherwise set forth in this Release, I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their officers, directors, agents, servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys’ fees, damages, indemnities and obligations of every kind and nature, in law, equity or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed (other than any claim for indemnification I may have as a result of any third party action against me based on my employment with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to the date I execute this Release, including, but not limited to: all such claims and demands directly or indirectly arising out of or in any way connected with my employment with the Company or the termination of that employment, including, but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation; and claims pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended, the federal Age Discrimination in Employment Act of 1967, as amended (“ADEA”), the federal Employee Retirement Income Security Act of 1974, as amended, the federal Americans with Disabilities Act of 1990, the California Fair Employment and Housing Act, as amended, the New York City Human Rights Law, as amended, the Massachusetts Fair Employment Practices Law, as amended, the South Carolina Human Affairs Law, as amended, tort law, contract law, wrongful discharge, discrimination, fraud, defamation, emotional distress, and breach of the implied covenant of good faith and fair dealing; provided, however, that nothing in this paragraph shall be construed in any way to (1) release the Company from its obligation to indemnify me pursuant to the Company’s indemnification obligation pursuant to written agreement or applicable law; (2) release any claim by me against the Company relating to the validity or enforceability of this release or the Agreement; (3) prohibit me from exercising any non-waivable right to file a charge with the United States Equal Employment Opportunity Commission (“EEOC”), the National Labor Relations Board (“NLRB”), or any other government agency (provided, however, that I shall not be entitled to recover any monetary damages or to obtain non-monetary relief if the agency were to pursue any claims relating to my employment with the Company).
I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have to assert claims for age discrimination under applicable law, including under the ADEA. I also acknowledge that the consideration given under the Agreement for the waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as required by the ADEA, that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this Release; (B) I have the right to consult with an attorney prior to executing this Release; (C) I have twenty-one (21) days to consider this Release (although I may choose to voluntarily execute this Release earlier); (D) I have seven (7) days following my execution of this Release to revoke the Release by providing a written notice of revocation to the
A-1
Company’s Chief Executive Officer; and (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth (8th) day after I execute this Release (provided that I do not revoke it).
I hereby represent that I have been paid all compensation owed and for all hours worked, I have received all the leave and leave benefits and protections for which I am eligible, pursuant to the federal Family and Medical Leave Act, any Company policy or applicable law, and I have not suffered any on-the-job injury or illness for which I have not already filed a workers’ compensation claim.
I agree that I will not make any disparaging statements regarding the Company or its officers, directors, shareholders, members, agents or products jointly or severally. The foregoing shall not be violated by truthful statements in response to legal process, required governmental testimony or filings, or administrative or arbitral proceedings (including, without limitation, depositions in connection with such proceedings).
EXECUTIVE:
Signature
Printed Name
Date:
A-2
EXHIBIT B
RELEASE
(INDIVIDUAL AND GROUP TERMINATION – UNDER AGE 40)
Certain capitalized terms used in this Release are defined in the Executive Employment Agreement (the “Agreement”) which I have executed and of which this Release is a part.
I hereby confirm my obligations under the Confidentiality Agreement (or other comparable agreement that I have signed, if any).
Except as otherwise set forth in this Release, I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their officers, directors, agents, servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys’ fees, damages, indemnities and obligations of every kind and nature, in law, equity or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed (other than any claim for indemnification I may have as a result of any third party action against me based on my employment with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to the date I execute this Release, including, but not limited to: all such claims and demands directly or indirectly arising out of or in any way connected with my employment with the Company or the termination of that employment, including, but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation; and claims pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended, the federal Employee Retirement Income Security Act of 1974, as amended, the federal Americans with Disabilities Act of 1990, the California Fair Employment and Housing Act, as amended, the New York City Human Rights Law, as amended, the Massachusetts Fair Employment Practices Law, as amended, the South Carolina Human Affairs Law, as amended, tort law, contract law, wrongful discharge, discrimination, fraud, defamation, emotional distress, and breach of the implied covenant of good faith and fair dealing; provided, however, that nothing in this paragraph shall be construed in any way to (1) release the Company from its obligation to indemnify me pursuant to the Company’s indemnification obligation pursuant to written agreement or applicable law; (2) release any claim by me against the Company relating to the validity or enforceability of this release or the Agreement; (3) prohibit me from exercising any non-waivable right to file a charge with the United States Equal Employment Opportunity Commission (“EEOC”), the National Labor Relations Board (“NLRB”), or any other government agency (provided, however, that I shall not be entitled to recover any monetary damages or to obtain non-monetary relief if the agency were to pursue any claims relating to my employment with the Company).
I acknowledge that the consideration given under the Agreement for the waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this Release; (B) I have the right to consult with an attorney prior to executing this Release; and (C) I have twenty-one (21) days to consider this Release (although I may choose to voluntarily execute this Release earlier).
I hereby represent that I have been paid all compensation owed and for all hours worked, I have received all the leave and leave benefits and protections for which I am eligible, pursuant to the federal Family and Medical Leave Act, any Company policy or applicable law, and I have not suffered any on-the-job injury or illness for which I have not already filed a workers’ compensation claim.
B-1
I agree that I will not make any disparaging statements regarding the Company or its officers, directors, shareholders, members, agents or products jointly or severally. The foregoing shall not be violated by truthful statements in response to legal process, required governmental testimony or filings, or administrative or arbitral proceedings (including, without limitation, depositions in connection with such proceedings).
EXECUTIVE:
Signature
Printed Name
Date:
B-2
EXHIBIT C
RELEASE
(GROUP TERMINATION – AGE 40 OR OLDER)
Certain capitalized terms used in this Release are defined in the Executive Employment Agreement (the “Agreement”) which I have executed and of which this Release is a part.
I hereby confirm my obligations under the Confidentiality Agreement (or other comparable agreement that I have signed, if any).
Except as otherwise set forth in this Release, I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their officers, directors, agents, servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys’ fees, damages, indemnities and obligations of every kind and nature, in law, equity or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed (other than any claim for indemnification I may have as a result of any third party action against me based on my employment with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to the date I execute this Release, including, but not limited to: all such claims and demands directly or indirectly arising out of or in any way connected with my employment with the Company or the termination of that employment, including, but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation; and claims pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended, the federal Age Discrimination in Employment Act of 1967, as amended (“ADEA”), the federal Employee Retirement Income Security Act of 1974, as amended, the federal Americans with Disabilities Act of 1990, the California Fair Employment and Housing Act, as amended, the New York City Human Rights Law, as amended, the Massachusetts Fair Employment Practices Law, as amended, the South Carolina Human Affairs Law, as amended, tort law, contract law, wrongful discharge, discrimination, fraud, defamation, emotional distress, and breach of the implied covenant of good faith and fair dealing; provided, however, that nothing in this paragraph shall be construed in any way to (1) release the Company from its obligation to indemnify me pursuant to the Company’s indemnification obligation pursuant to written agreement or applicable law; (2) release any claim by me against the Company relating to the validity or enforceability of this release or the Agreement; (3) prohibit me from exercising any non-waivable right to file a charge with the United States Equal Employment Opportunity Commission (“EEOC”), the National Labor Relations Board (“NLRB”), or any other government agency (provided, however, that I shall not be entitled to recover any monetary damages or to obtain non-monetary relief if the agency were to pursue any claims relating to my employment with the Company).
I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have to assert claims for age discrimination under applicable law, including under the ADEA. I also acknowledge that the consideration given under the Agreement for the waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as required by the ADEA, that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this Release; (B) I have the right to consult with an attorney prior to executing this Release; (C) I have forty-five (45) days to consider this Release (although I may choose to voluntarily execute this Release earlier); (D) I have seven (7) days following my execution of this Release to revoke the Release by providing a written notice of revocation to the Company’s Chief
C-1
Executive Officer; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a “group termination” under the ADEA, including a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
I hereby represent that I have been paid all compensation owed and for all hours worked, I have received all the leave and leave benefits and protections for which I am eligible, pursuant to the federal Family and Medical Leave Act, any Company policy or applicable law, and I have not suffered any on-the-job injury or illness for which I have not already filed a workers’ compensation claim.
I agree that I will not engage in any conduct that is injurious to the reputation of the Company or its parents, subsidiaries and affiliates, including but not limited to disparagement of the Company, its officers, Board members, employees and shareholders. The foregoing shall not be violated by a statement made in a deposition, trial or administrative proceeding in response to legal process; by any statement made to a government agency; or whenever I make any statement to a court, administrative tribunal or government agency as required by law.
EXECUTIVE:
Signature
Printed Name
Date:
C-2
Exhibit 99.1
Syndax Pharmaceuticals Announces Appointment of Neil Gallagher, M.D., Ph.D. as President, Head of Research and Development
- Neil Gallagher, M.D., Ph.D. brings to Syndax over 20 years of experience as a leading oncology drug developer -
WALTHAM, Mass., March 30, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Neil Gallagher, M.D., Ph.D., to the role of President, Head of Research and Development (R&D), effective April 10, 2023. Dr. Gallagher brings to Syndax over 20 years of industry experience, most recently serving as Chief Medical Officer, Vice President, Head of Development at AbbVie, where he led multiple development programs through approval globally and oversaw asset strategy and portfolio management across several therapeutic areas, including oncology.
“Neil is a preeminent, global oncology drug developer with deep expertise and a strong track record of successful drug approvals, notably in hematologic malignancies with Venclexta®, an important new agent for patients with acute leukemia,” said Michael A. Metzger, Chief Executive Officer. “Neil’s passion for bringing innovative drugs to patients and his experience across all stages of drug development will be instrumental as we advance revumenib and axatilimab through anticipated pivotal data readouts and two planned regulatory filings expected in 2023. I look forward to Neil’s many contributions as we work to bring novel products to patients and pursue opportunities to expand our pipeline of best-in-class medicines.”
Prior to Assuming his role as Chief Medical Officer, Vice President, Head of Development at AbbVie, Dr. Gallagher served as the company’s Head of Global Oncology Development, a role in which he expanded the hematology and solid tumor portfolio while strengthening precision medicine and companion diagnostic capabilities. Prior to joining AbbVie, he served as Head of Development for Oncology and Inflammation at Amgen. Dr. Gallagher previously spent a decade at Novartis, where he led several development and clinical programs across the portfolio. While at Novartis, he also led cross-functional global program teams responsible for chronic myeloid leukemia and gastrointestinal stromal tumor development as well as other hematology oncology indications. Earlier in his career, he was a Senior Medical Director at AstraZeneca and later Director of Clinical Development at Astex Therapeutics. Dr. Gallagher completed his Fellowship in Gynecological Oncology at the Institute for Cancer Studies, University of Birmingham, UK. Dr. Gallagher received his medical degree from Trinity College, Dublin.
“Syndax has set itself apart as a leader in targeted oncology with late-stage, first- and best-in-class molecules based on their compelling clinical profiles. Revumenib and axatilimab have the potential to become the standard of care in their respective disease areas,” said Dr. Gallagher. “It is an exciting time to lead R&D at Syndax as the Company looks to expand the potential indications for revumenib and axatilimab. I am delighted to join this impressive Syndax team and leverage our collective expertise to develop differentiated therapies that could transform the lives of cancer patients and create significant long-term value.”
“Briggs’ leadership and partnership have been instrumental in building Syndax into the world-class oncology company that it is today,” said Mr. Metzger. “This is an ideal time for Briggs to transition his role as President of R&D to Neil who will lead us through the next stage of Syndax’s growth. We look forward to continuing to work with Briggs, who will remain in his current role as a member of the Board of Directors.”
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company’s pipeline include revumenib, a highly selective inhibitor of the menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, both currently in pivotal clinical trials. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend,” “believe” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials, the reporting of clinical data for Syndax’s product candidates, the progress of regulatory submissions and approvals, including the potential use of Syndax’s product candidates to treat various cancer indications and fibrotic diseases. Many factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes in expected or existing competition; changes in
the regulatory environment; the impact of macroeconomic conditions (such as COVID-19 pandemic, the Russia-Ukraine war, inflation, among others) on Syndax’s business and that of the third parties on which Syndax depends, including delaying or otherwise disrupting Syndax’s clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity; failure of Syndax’s collaborators to support or advance collaborations or product candidates; and unexpected litigation or other disputes. Other factors that may cause Syndax’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
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end
Document And Entity Information |
Mar. 29, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Mar. 29, 2023 |
Entity Registrant Name | SYNDAX PHARMACEUTICALS, INC. |
Entity Central Index Key | 0001395937 |
Entity Emerging Growth Company | false |
Securities Act File Number | 001-37708 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 32-0162505 |
Entity Address, Address Line One | Building D |
Entity Address, Address Line Two | Floor 3 |
Entity Address, Address Line Three | 35 Gatehouse Drive |
Entity Address, City or Town | Waltham |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02451 |
City Area Code | (781) |
Local Phone Number | 419-1400 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock |
Trading Symbol | SNDX |
Security Exchange Name | NASDAQ |
-8?20$3;8T.P6BP^0"X99K>]9!:G
M
BH)LF!8<9#])A -08Q1:UP2NIRC$N: $;/>(UZ7D16^(Y(CW*Y%!B]&S^]1U__
M&CVB1\*^3UV)T1WWE@%F$=+1(HK"CF&LU^N6/R-,9[,S?/T"1GIZ_@XU=>S'*;P*XYAIS"1P]5[;S/@VOEKR'?P1
MO30<(W7J\, FA]NLC1!YD "H/!\4=N5 4[HP5E:SQ&)-";.=7*CTIA"ZB#;+)>>>XZY$QPSV 6.F<1%A]CE"-V]?,'Q
MLJYJA*NI!LA2+6/" F*94DS,F#@FF8,8U01I52728#[0